HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Klubo-Gwiezdzinska, J. Articles by Kardymowicz, H. Search for Related Content PubMed PubMed Citation Articles by Klubo-Gwiezdzinska, J. Articles by Kardymowicz, H.

The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter

¹ Departments of Endocrinology and Diabetology and ² Pathobiochemistry and Clinical Biochemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, ul. M. Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland and ³ Department of Laboratory Diagnostics, Oncology Centre in Bydgoszcz, ul. dr I.Romanowskiej 2, 85-796 Bydgoszcz, Poland

(Correspondence should be addressed to J Klubo-Gwiezdzinska who is now at Klinika Endokrynologii i Diabetologii, Szpitala Uniwersyteckiego im. A. Jurasza w Bydgoszczy, ul. M. Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland; Email: adamgw{at}poczta.onet.pl)

Background: One of the important proangiogenic factors involved in the growth of normal and neoplastic tissues is vascular endothelial growth factor (VEGF).

Aim: We hypothesized that serum VEGF concentration would differ between patients with metastatic and non-metastatic thyroid cancer, multinodular goiter, and healthy subjects. We also hypothesized that endogenous TSH stimulation would affect serum VEGF level.

Subjects and methods: The study group consisted of 71 patients (62 females and 9 males), aged 44.9 ± 12.3 years, with differentiated thyroid cancer (50 papillary, 17 follicular, and 4 oxyphilic), treated in our department during the years 2003–2006. All patients had undergone total or near-total thyroidectomy and radioactive iodine treatment, that had resulted in remission in 59 patients and persistent/recurrent disease in 12 patients. The study included two control groups: 30 patients with nontoxic multinodular goiter and 30 healthy subjects.

Results: Serum VEGF concentrations were significantly higher in patients with distant metastases than those in remission or healthy patients. (423.4 vs 217.6 vs 235.55 pg/ml respectively, P < 0.05). This was not observed in patients with locoregional metastases. During endogenous TSH stimulation, VEGF decreased significantly (215.3 vs 169.6 pg/ml, P < 0.05). Patients with multinodular goiter showed significantly lower VEGF concentrations than the remaining study groups.

Conclusions: Serum VEGF concentration might be used as an additional marker of thyroid cancer with distant metastases, but its interpretation should be undertaken very cautiously. Endogenous TSH stimulation decreases VEGF levels in patients either with or without thyroid tissue, suggesting that its regulatory effects are through receptors located outside the thyrocytes.

This article has been cited by other articles:

				M. Joao Bugalho, D. Madureira, C. Espadinha, A. Paula Font, and L. G Sobrinho Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma Eur. J. Endocrinol., August 1, 2008; 159(2): 167 - 169. [Abstract] [Full Text] [PDF]